Polar Capital ISIN IE000Q6Q6VA4

Polar Capital Biotechnology Fund

Polar Capital Biotechnology Fund is an active equity fund from Polar Capital, ISIN IE000Q6Q6VA4.

  • Active
  • Equity
  • Global
  • Fund size (GBP) £2.9B

The investment objective of the Fund is to preserve capital and achieve long term capital appreciation.

How the fund has returned, and where it ranks among peers. Returns to Sep 2026 end, GBP net total return.
–
1 year return
–
3 year return
–
5 year return
Daily NAV, percent change from the start of the range. Source: FE fundinfo.
  • 1 month −7.2%
  • 3 months −8.0%
  • Volatility, 1 year 25.6%
  • Ongoing charge (OCF)
  • Fund size (GBP) £2.9B

What the fund holds

Where the money is: sectors, countries and largest holdings. As supplied by FE fundinfo, last updated 5 Oct 2026. Swipe or use the arrows for more panels.

By sector

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 5 Oct 2026.
Health Care91.6%
Money Market8.4%

By country

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 5 Oct 2026.
USA73.5%
Netherlands5.6%
Canada3.9%
See all countriesA free account shows the full list.

By asset class

Spot concentrations at a glance. Share of the fund's portfolio, as supplied by FE fundinfo, last updated 5 Oct 2026.
US Equities73.5%
Money Market8.4%
Dutch Equities5.6%
See all asset classesA free account shows the full list.

Largest holdings

The biggest positions, and how concentrated the fund is. As supplied by FE fundinfo, last updated 5 Oct 2026.
  1. 1. AMGEN INC.4.9%
  2. 2. MADRIGAL PHARMACEUTICALS INC4.5%
  3. 3. ARGENX SE4.4%
  4. 4. INSMED INCORPORATED4.1%
  5. 5. ALNYLAM PHARMACEUTICALS, INC.4.1%
See all holdingsA free account shows the full list.

Macro events and this fund

Recent events linked to this fund by its country and sector exposure, and how it moved after. A measured move, not a cause.

Performance, risk and facts

Judge return, risk and cost before a client conversation. Relative return uses the chart's time range. Facts as reported by the manager.

Against its benchmark

How the fund compares with its benchmark over the same period.

Risk

How bumpy the ride has been, plus the regulatory risk rating.
Volatility, 1 year25.6%
Scale 0 to 40%
Largest fall from a peak (maximum drawdown), 1 year
−12.5%

Volatility and maximum drawdown: calculated by Funds Benchmark, as at 30 Sep 2026.

Fund facts

Legal and cost facts for a client note. As reported by the manager.
ISIN
IE000Q6Q6VA4
Fund manager
Powell, Pinniger
Management company
FundRock Management Company (Ireland) Limited
Depositary
Northern Trust International Fund Administration Services (Ireland) Limited
Benchmark
NASDAQ Biotechnology Net Total Return Index (USD)
Ongoing charge
Share class launch date
28 Nov 2025
Domicile
IE
Fund type
open-ended fund

What a sum would have become

What an amount would have grown to over the period.
n/a

Past performance is not a reliable guide to future returns. Capital is at risk. Source: FE fundinfo. Returns are GBP net total return to month end unless stated. Headline returns to Sep 2026. Fund size is shown in GBP.

Managed by Polar Capital

View every Polar Capital fund on Funds Benchmark →

Other FE GL Equity Health Care funds

Sector: FE GL Equity Health Care

View the FE GL Equity Health Care sector overview — top funds, average performance, exposure →

Top country exposure